Abstract
BACKGROUND: Leukotrienes have been implicated in the mediation of airway obstruction induced by hyperventilation of cold dry air in asthmatic subjects. The effect of a novel inhibitor of 5-lipoxygenase activating protein, BAYx 1005, on the bronchospastic response to cold dry air hyperventilation was investigated in asthmatic patients. METHODS: After a screening cold dry air hyperventilation challenge to document cold air responsiveness, 16 asthmatic subjects (baseline forced expiratory volume in one second (FEV1) > 60% of predicted) underwent cold air challenge three hours after receiving 750 mg of BAYx 1005 or placebo using a randomised, double blind, crossover design. Leukotriene synthesis inhibition was estimated by measuring the concentration of leukotriene B4 in whole blood stimulated with calcium ionophore A21387. RESULTS: Treatment with BAYx 1005 produced a 34% (95% CI 11 to 63) increase in the amount of cold air minute ventilation required for a 10% decrease in FEV1 (PD10VE) compared with placebo (mean (SE) 37.6 (1.12) 1/min compared with 28.0 (1.13) 1/min, p < 0.006). The PD20VE increased 19% (95% CI 8 to 31) after treatment with BAYx 1005 compared with placebo (57.3(1.10)1/min versus 48.1 (1.10) 1/min, p < 0.002). Treatment with BAYx 1005 produced a 15.4% decrease in ionophore-stimulated LTB4 production, while treatment with placebo produced a 7.1% increase in ex vivo LTB4 (p < 0.02). CONCLUSIONS: Treatment with BAYx 1005, a novel inhibitor of leukotriene synthesis, produced a significant blunting of cold dry air responsiveness consistent with the hypothesis that leukotrienes mediate part of the bronchoconstriction induced by hyperventilation of cold dry air.
Full Text
The Full Text of this article is available as a PDF (133.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Diamant Z., Timmers M. C., van der Veen H., Friedman B. S., De Smet M., Depré M., Hilliard D., Bel E. H., Sterk P. J. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol. 1995 Jan;95(1 Pt 1):42–51. doi: 10.1016/s0091-6749(95)70151-6. [DOI] [PubMed] [Google Scholar]
- Friedman B. S., Bel E. H., Buntinx A., Tanaka W., Han Y. H., Shingo S., Spector R., Sterk P. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis. 1993 Apr;147(4):839–844. doi: 10.1164/ajrccm/147.4.839. [DOI] [PubMed] [Google Scholar]
- Hatzelmann A., Fruchtmann R., Mohrs K. H., Raddatz S., Müller-Peddinghaus R. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. Biochem Pharmacol. 1993 Jan 7;45(1):101–111. doi: 10.1016/0006-2952(93)90382-7. [DOI] [PubMed] [Google Scholar]
- Henderson W. R., Jr The role of leukotrienes in inflammation. Ann Intern Med. 1994 Nov 1;121(9):684–697. doi: 10.7326/0003-4819-121-9-199411010-00010. [DOI] [PubMed] [Google Scholar]
- Israel E., Dermarkarian R., Rosenberg M., Sperling R., Taylor G., Rubin P., Drazen J. M. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990 Dec 20;323(25):1740–1744. doi: 10.1056/NEJM199012203232505. [DOI] [PubMed] [Google Scholar]
- Israel E., Fischer A. R., Rosenberg M. A., Lilly C. M., Callery J. C., Shapiro J., Cohn J., Rubin P., Drazen J. M. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1447–1451. doi: 10.1164/ajrccm/148.6_Pt_1.1447. [DOI] [PubMed] [Google Scholar]
- Israel E., Juniper E. F., Callaghan J. T., Mathur P. N., Morris M. M., Dowell A. R., Enas G. G., Hargreave F. E., Drazen J. M. Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis. 1989 Nov;140(5):1348–1353. doi: 10.1164/ajrccm/140.5.1348. [DOI] [PubMed] [Google Scholar]
- Taylor I. K., O'Shaughnessy K. M., Fuller R. W., Dollery C. T. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991 Mar 23;337(8743):690–694. doi: 10.1016/0140-6736(91)90277-v. [DOI] [PubMed] [Google Scholar]